Empagliflozin
- PDF / 169,952 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 17 Downloads / 180 Views
1 S
Euglycaemic diabetic ketoacidosis: case report A 42-year-old woman developed euglycaemic diabetic ketoacidosis (eDKA) during treatment with empagliflozin for type 2 diabetes mellitus (DM). The woman, who had a 10-year history of type 2 DM, presented with vomiting, dyspnoea and nausea. Vital signs revealed a pulse rate of 110 beats/min, a temperature of 36.1°C, BP of 127/65mm Hg and a respiratory rate of 18 breaths/min. Laboratory tests revealed blood glucose as 196 mg/dL, serum bicarbonate of 8.9 mmol/L , anion gap of 20 mEq/L, blood pH of 7.08 and urine ketones 2+. It was reported that she had been receiving oral empagliflozin 10 mg/day for a year. Additionally, she was receiving metformin concomitantly.The diagnosis of coronavirus disease 2019 (COVID-19) was ruled out as a result of the final evaluation. Meanwhile, her acidosis increased. Based on these clinical presentation and findings, eDKA due to empagliflozin use was diagnosed [time to reaction onset not clearly stated]. The woman was taken to the intensive care unit for treatment. Isotonic fluid replacement and insulin were initiated. To the treatment, glucose [dextrose] was also included, and sodium bicarbonate was given for acidosis. Oral anti-diabetic medications were stopped. After 12 hours, following the treatment, her acidosis resolved. Approximately 30 hours later, urine ketones were negative. She was discharged with insulin aspart and insulin glargine. Ozer O, et al. Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic. Journal of the College of Physicians and 803517338 Surgeons Pakistan 30 (Suppl. 2): S110-S111, No. 10, Oct 2020. Available from: URL: http://doi.org/10.29271/jcpsp.2020.supp2.110
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
